Complex PK/PD modelling for cannabidiol as a new agent in patients with schizophrenia
Aim of this research project is to support CBD research by building a population PK/PD model that describes the complex associations of dose, biomarkers and response. Based on data from clinical trials a pharmacokinetic (PK) model will be developed to describe the standard PK parameters (clearance, volume of distribution, etc.) in patients with schizophrenia. NONMEM is the reference software for compartmental population PK modelling. Further software tools will be explored to provide other methods for (non-)compartmental modelling.